Chronic obstructive pulmonary disease drugs market: Driving factors, Industry challenges, Segmentation, Key vendor analysis, Leading countries, and Market size and forecast 2023-2027 - Technavio

NEW YORK, Jan. 23, 2023 /PRNewswire/ --

In-depth analysis provided in the report includes:

• Current and future market trends to highlight market conditions
• Comparative analysis of the market and its segments for the historic period of 2017 - 2021
• Market drivers and market impediments and their impact on market growth
• Positioning of market players and their business strategy analysis
• Download a Sample Now!

Chronic obstructive pulmonary disease drugs market size & segmentation analysis

The chronic obstructive pulmonary disease drugs market is estimated to grow at a CAGR of 6.09% between 2022 and 2027. The size of the market is forecast to increase by USD 6,654.49 million. The chronic obstructive pulmonary disease drugs market is segmented based on product, distribution channel, and geography.

• Based on the product, the chronic obstructive pulmonary disease drugs market is segmented into combination therapy and monotherapy.
• Based on the distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.
• Based on geography, the chronic obstructive pulmonary disease drugs market is segmented into North America, Europe, Asia, and Rest of World.
• For insights on the market contribution of each segment, Buy the report!

Chronic obstructive pulmonary disease drugs market: Country-level analysis

The countries covered in the chronic obstructive pulmonary disease drugs market report are the US and Canada (North America); the UK, Germany, France, and the Rest of Europe (Europe); China, India, Vietnam, and others (Asia); Saudi Arabia, South Africa, Brazil, and others (Rest of World).

• North America will account for 50% of the market growth during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. The growth in North America can be attributed to several factors, including the rising incidence of COPD, the availability of reimbursement schemes, and approvals for new triple combination drugs for the treatment of COPD.
• The rising incidence of COPD is a major driving factor for the COPD drugs market in North America.  As per the National Institutes of Health (NIH), COPD is one of the leading causes of death in the US, and in 2020, it affected 16 million people in the US. Risk factors for COPD, such as smoking and air pollutants, have also been increasing drastically over the past three decades. These factors will facilitate market growth during the forecast period.

The geographic landscape of the report also provides market-impacting factors and changes that impact current and future trends. For detailed information, Request a sample!

Chronic obstructive pulmonary disease drugs market: Dynamics & Insights

Technavio's research report on the chronic obstructive pulmonary disease drugs market provides analysis and insights about the various drivers, along with key challenges, that impact the market throughout the forecast period.

The increasing prevalence of COPD is accelerating the growth of the chronic obstructive pulmonary disease drug market globally. COPD is a chronic non-communicable lifestyle-related disease that progresses steadily without medical intervention. There are several lifestyle-related factors, such as smoking, exposure to biomass fuel, and air pollution, which increase the risk of developing COPD. Because of the significant prevalence of these factors in the environment worldwide, COPD has become a leading cause of mortality and morbidity globally.  As per Natalie Terzikhan et al., COPD is considered the third-leading cause of death worldwide.

The high cost of COPD clinical trials is a major challenge hindering the growth of the global chronic obstructive pulmonary disease drug market. The high cost of clinical trials for respiratory diseases is a major challenge for the global COPD drug market. The incidence of  COPD has increased rapidly in recent years. According to ClinicalTrials.gov, there are few ongoing clinical trials for respiratory diseases. About 39 studies have been done on COPD. The costs associated with each stage of a clinical trial limit the number of studies that can be conducted in clinical trials. Therefore, the high cost of conducting clinical trials in respiratory disorders will negatively impact the growth of the global COPD drugs market during the forecast period.

Chronic obstructive pulmonary disease drugs market: Competitive landscape and vendor analysis

Technavio's report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Some of the major players operating in the chronic obstructive pulmonary disease drugs market are AstraZeneca Plc, Exela Pharma Sciences LLC, GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd., Innoviva Inc., Lupin Ltd., Merck and Co. Inc., Mundipharma International Ltd., Novartis AG, Theravance Biopharma Inc., Vertex Pharmaceuticals Inc., Viatris Inc., Boehringer Ingelheim International GmbH, Cadila Pharmaceuticals Ltd., and CHIESI Farmaceutici SpA, Cipla Ltd., among others. For insights on the vendor offerings, Download a PDF sample!

Related Reports:

The antidepressants drugs market share is expected to increase to USD 5.22 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 5.44%. The rising prevalence of depression is notably driving the antidepressant drugs market growth, although factors such as social stigma associated with depression and lack of awareness among people may impede the market growth.

The polycystic kidney disease drugs market share is expected to increase by USD 510.69 million from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 6.7%. The high prevalence of chronic kidney diseases is notably driving the polycystic kidney disease drug market growth, although factors such as lack of approved drugs may impede the market growth. 

Gain instant access to 17,000+ market research reports. 

Technavio's SUBSCRIPTION platform

Table of Contents:

1 Executive Summary

• 1.1 Market Overview
• Exhibit 01: Executive Summary – Chart on Market Overview
• Exhibit 02: Executive Summary – Data Table on Market Overview
• Exhibit 03: Executive Summary – Chart on Global Market Characteristics
• Exhibit 04: Executive Summary – Chart on Market by Geography
• Exhibit 05: Executive Summary – Chart on Market Segmentation by Product
• Exhibit 06: Executive Summary – Chart on Market Segmentation by Distribution Channel
• Exhibit 07: Executive Summary – Chart on Incremental Growth
• Exhibit 08: Executive Summary – Data Table on Incremental Growth
• Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem
• Exhibit 10: Parent market
• Exhibit 11: Market Characteristics

3 Market Sizing

• 3.1 Market Definition
• Exhibit 12: Offerings of vendors included in the market definition

• 3.2 Market segment analysis 
• Exhibit 13: Market segments

• 3.3 Market size 2022

• 3.4 Market outlook: Forecast for 2022-2027 
• Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
• Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
• Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
• Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

• 4.1 Global chronic obstructive pulmonary disease drugs market 2017 - 2021 
• Exhibit 18: Historic Market Size – Data Table on Global chronic obstructive pulmonary disease drugs market 2017 - 2021 ($ million)

• 4.2 Product Segment Analysis 2017 - 2021 
• Exhibit 19: Historic Market Size – Product Segment 2017 - 2021 ($ million)

• 4.3 Distribution channel Segment Analysis 2017 - 2021 
• Exhibit 20: Historic Market Size – Distribution channel Segment 2017 - 2021 ($ million)

• 4.4 Geography Segment Analysis 2017 - 2021 
• Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ million)

• 4.5 Country Segment Analysis 2017 - 2021 
• Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ million)

5 Five Forces Analysis

• 5.1 Five forces summary
• Exhibit 23: Five forces analysis - Comparison between 2022 and 2027

• 5.2 Bargaining power of buyers 
• Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027

• 5.3 Bargaining power of suppliers 
• Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027

• 5.4 Threat of new entrants 
• Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027

• 5.5 Threat of substitutes 
• Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027

• 5.6 Threat of rivalry
• Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027

• 5.7 Market condition
• Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

6 Market Segmentation by Product

• 6.1 Market segments
• Exhibit 30: Chart on Product - Market share 2022-2027 (%)
• Exhibit 31: Data Table on Product - Market share 2022-2027 (%)

• 6.2 Comparison by Product 
• Exhibit 32: Chart on Comparison by Product
• Exhibit 33: Data Table on Comparison by Product

• 6.3 Combination therapy - Market size and forecast 2022-2027 
• Exhibit 34: Chart on Combination therapy - Market size and forecast 2022-2027 ($ million)
• Exhibit 35: Data Table on Combination therapy - Market size and forecast 2022-2027 ($ million)
• Exhibit 36: Chart on Combination therapy - Year-over-year growth 2022-2027 (%)
• Exhibit 37: Data Table on Combination therapy - Year-over-year growth 2022-2027 (%)

• 6.4 Monotherapy - Market size and forecast 2022-2027 
• Exhibit 38: Chart on Monotherapy - Market size and forecast 2022-2027 ($ million)
• Exhibit 39: Data Table on Monotherapy - Market size and forecast 2022-2027 ($ million)
• Exhibit 40: Chart on Monotherapy - Year-over-year growth 2022-2027 (%)
• Exhibit 41: Data Table on Monotherapy - Year-over-year growth 2022-2027 (%)

• 6.5 Market opportunity by Product 
• Exhibit 42: Market opportunity by Product ($ million)

7 Market Segmentation by Distribution Channel

• 7.1 Market segments
• Exhibit 43: Chart on Distribution Channel - Market share 2022-2027 (%)
• Exhibit 44: Data Table on Distribution Channel - Market share 2022-2027 (%)

• 7.2 Comparison by Distribution Channel 
• Exhibit 45: Chart on Comparison by Distribution Channel
• Exhibit 46: Data Table on Comparison by Distribution Channel

• 7.3 Hospital pharmacies - Market size and forecast 2022-2027 
• Exhibit 47: Chart on Hospital pharmacies - Market size and forecast 2022-2027 ($ million)
• Exhibit 48: Data Table on Hospital pharmacies - Market size and forecast 2022-2027 ($ million)
• Exhibit 49: Chart on Hospital pharmacies - Year-over-year growth 2022-2027 (%)
• Exhibit 50: Data Table on Hospital pharmacies - Year-over-year growth 2022-2027 (%)

• 7.4 Retail pharmacies - Market size and forecast 2022-2027 
• Exhibit 51: Chart on Retail pharmacies - Market size and forecast 2022-2027 ($ million)
• Exhibit 52: Data Table on Retail pharmacies - Market size and forecast 2022-2027 ($ million)
• Exhibit 53: Chart on Retail pharmacies - Year-over-year growth 2022-2027 (%)
• Exhibit 54: Data Table on Retail pharmacies - Year-over-year growth 2022-2027 (%)

• 7.5 Online pharmacies - Market size and forecast 2022-2027 
• Exhibit 55: Chart on Online pharmacies - Market size and forecast 2022-2027 ($ million)
• Exhibit 56: Data Table on Online pharmacies - Market size and forecast 2022-2027 ($ million)
• Exhibit 57: Chart on Online pharmacies - Year-over-year growth 2022-2027 (%)
• Exhibit 58: Data Table on Online pharmacies - Year-over-year growth 2022-2027 (%)

• 7.6 Market opportunity by Distribution Channel 
• Exhibit 59: Market opportunity by Distribution Channel ($ million)

8 Customer Landscape

• 8.1 Customer landscape overview 
• Exhibit 60: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

• 9.1 Geographic segmentation 
• Exhibit 61: Chart on Market share by geography 2022-2027 (%)
• Exhibit 62: Data Table on Market share by geography 2022-2027 (%)

• 9.2 Geographic comparison 
• Exhibit 63: Chart on Geographic comparison
• Exhibit 64: Data Table on Geographic comparison

• 9.3 North America - Market size and forecast 2022-2027 
• Exhibit 65: Chart on North America - Market size and forecast 2022-2027 ($ million)
• Exhibit 66: Data Table on North America - Market size and forecast 2022-2027 ($ million)
• Exhibit 67: Chart on North America - Year-over-year growth 2022-2027 (%)
• Exhibit 68: Data Table on North America - Year-over-year growth 2022-2027 (%)

• 9.4 Europe - Market size and forecast 2022-2027 
• Exhibit 69: Chart on Europe - Market size and forecast 2022-2027 ($ million)
• Exhibit 70: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
• Exhibit 71: Chart on Europe - Year-over-year growth 2022-2027 (%)
• Exhibit 72: Data Table on Europe - Year-over-year growth 2022-2027 (%)

• 9.5 Asia - Market size and forecast 2022-2027 
• Exhibit 73: Chart on Asia - Market size and forecast 2022-2027 ($ million)
• Exhibit 74: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
• Exhibit 75: Chart on Asia - Year-over-year growth 2022-2027 (%)
• Exhibit 76: Data Table on Asia - Year-over-year growth 2022-2027 (%)

• 9.6 Rest of World (ROW) - Market size and forecast 2022-2027 
• Exhibit 77: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
• Exhibit 78: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
• Exhibit 79: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
• Exhibit 80: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)

• 9.7 US - Market size and forecast 2022-2027 
• Exhibit 81: Chart on US - Market size and forecast 2022-2027 ($ million)
• Exhibit 82: Data Table on US - Market size and forecast 2022-2027 ($ million)
• Exhibit 83: Chart on US - Year-over-year growth 2022-2027 (%)
• Exhibit 84: Data Table on US - Year-over-year growth 2022-2027 (%)

• 9.8 UK - Market size and forecast 2022-2027 
• Exhibit 85: Chart on UK - Market size and forecast 2022-2027 ($ million)
• Exhibit 86: Data Table on UK - Market size and forecast 2022-2027 ($ million)
• Exhibit 87: Chart on UK - Year-over-year growth 2022-2027 (%)
• Exhibit 88: Data Table on UK - Year-over-year growth 2022-2027 (%)

• 9.9 Canada - Market size and forecast 2022-2027 
• Exhibit 89: Chart on Canada - Market size and forecast 2022-2027 ($ million)
• Exhibit 90: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
• Exhibit 91: Chart on Canada - Year-over-year growth 2022-2027 (%)
• Exhibit 92: Data Table on Canada - Year-over-year growth 2022-2027 (%)

• 9.10 Germany - Market size and forecast 2022-2027 
• Exhibit 93: Chart on Germany - Market size and forecast 2022-2027 ($ million)
• Exhibit 94: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
• Exhibit 95: Chart on Germany - Year-over-year growth 2022-2027 (%)
• Exhibit 96: Data Table on Germany - Year-over-year growth 2022-2027 (%)

• 9.11 Japan - Market size and forecast 2022-2027 
• Exhibit 97: Chart on Japan - Market size and forecast 2022-2027 ($ million)
• Exhibit 98: Data Table on Japan - Market size and forecast 2022-2027 ($ million)
• Exhibit 99: Chart on Japan - Year-over-year growth 2022-2027 (%)
• Exhibit 100: Data Table on Japan - Year-over-year growth 2022-2027 (%)

• 9.12 Market opportunity by geography 
• Exhibit 101: Market opportunity by geography ($ million)

10 Drivers, Challenges, and Trends

• 10.1 Market drivers

• 10.2 Market challenges

• 10.3 Impact of drivers and challenges 
• Exhibit 102: Impact of drivers and challenges in 2022 and 2027

• 10.4 Market trends

11 Vendor Landscape

• 11.1 Overview

• 11.2 Vendor landscape
• Exhibit 103: Overview on Criticality of inputs and Factors of differentiation

• 11.3 Landscape disruption
• Exhibit 104: Overview on factors of disruption

• 11.4 Industry risks
• Exhibit 105: Impact of key risks on business

12 Vendor Analysis

• 12.1 Vendors covered
• Exhibit 106: Vendors covered

• 12.2 Market positioning of vendors 
• Exhibit 107: Matrix on vendor position and classification

• 12.3 AstraZeneca Plc
• Exhibit 108: AstraZeneca Plc - Overview
• Exhibit 109: AstraZeneca Plc - Product / Service
• Exhibit 110: AstraZeneca Plc - Key news
• Exhibit 111: AstraZeneca Plc - Key offerings

• 12.4 Boehringer Ingelheim International GmbH 
• Exhibit 112: Boehringer Ingelheim International GmbH - Overview
• Exhibit 113: Boehringer Ingelheim International GmbH - Business segments
• Exhibit 114: Boehringer Ingelheim International GmbH - Key news
• Exhibit 115: Boehringer Ingelheim International GmbH - Key offerings
• Exhibit 116: Boehringer Ingelheim International GmbH - Segment focus

• 12.5 Cadila Pharmaceuticals Ltd. 
• Exhibit 117: Cadila Pharmaceuticals Ltd. - Overview
• Exhibit 118: Cadila Pharmaceuticals Ltd. - Product / Service
• Exhibit 119: Cadila Pharmaceuticals Ltd. - Key offerings

• 12.6 Cipla Ltd.
• Exhibit 120: Cipla Ltd. - Overview
• Exhibit 121: Cipla Ltd. - Business segments
• Exhibit 122: Cipla Ltd. - Key news
• Exhibit 123: Cipla Ltd. - Key offerings
• Exhibit 124: Cipla Ltd. - Segment focus

• 12.7 Exela Pharma Sciences LLC 
• Exhibit 125: Exela Pharma Sciences LLC - Overview
• Exhibit 126: Exela Pharma Sciences LLC - Product / Service
• Exhibit 127: Exela Pharma Sciences LLC - Key offerings

• 12.8 GlaxoSmithKline Plc
• Exhibit 128: GlaxoSmithKline Plc - Overview
• Exhibit 129: GlaxoSmithKline Plc - Business segments
• Exhibit 130: GlaxoSmithKline Plc - Key offerings
• Exhibit 131: GlaxoSmithKline Plc - Segment focus

• 12.9 Lupin Ltd.
• Exhibit 132: Lupin Ltd. - Overview
• Exhibit 133: Lupin Ltd. - Product / Service
• Exhibit 134: Lupin Ltd. - Key news
• Exhibit 135: Lupin Ltd. - Key offerings

• 12.10 Merck and Co. Inc.
• Exhibit 136: Merck and Co. Inc. - Overview
• Exhibit 137: Merck and Co. Inc. - Business segments
• Exhibit 138: Merck and Co. Inc. - Key news
• Exhibit 139: Merck and Co. Inc. - Key offerings
• Exhibit 140: Merck and Co. Inc. - Segment focus

• 12.11 Mundipharma International Ltd. 
• Exhibit 141: Mundipharma International Ltd. - Overview
• Exhibit 142: Mundipharma International Ltd. - Product / Service
• Exhibit 143: Mundipharma International Ltd. - Key offerings

• 12.12 Novartis AG
• Exhibit 144: Novartis AG - Overview
• Exhibit 145: Novartis AG - Business segments
• Exhibit 146: Novartis AG - Key offerings
• Exhibit 147: Novartis AG - Segment focus

• 12.13 Shionogi and Co. Ltd. 
• Exhibit 148: Shionogi and Co. Ltd. - Overview
• Exhibit 149: Shionogi and Co. Ltd. - Product / Service
• Exhibit 150: Shionogi and Co. Ltd. - Key offerings

• 12.14 Sumitomo Pharma Co. Ltd. 
• Exhibit 151: Sumitomo Pharma Co. Ltd. - Overview
• Exhibit 152: Sumitomo Pharma Co. Ltd. - Business segments
• Exhibit 153: Sumitomo Pharma Co. Ltd. - Key offerings
• Exhibit 154: Sumitomo Pharma Co. Ltd. - Segment focus

• 12.15 Teva Pharmaceutical Industries Ltd. 
• Exhibit 155: Teva Pharmaceutical Industries Ltd. - Overview
• Exhibit 156: Teva Pharmaceutical Industries Ltd. - Business segments
• Exhibit 157: Teva Pharmaceutical Industries Ltd. - Key news
• Exhibit 158: Teva Pharmaceutical Industries Ltd. - Key offerings
• Exhibit 159: Teva Pharmaceutical Industries Ltd. - Segment focus

• 12.16 Theravance Biopharma Inc. 
• Exhibit 160: Theravance Biopharma Inc. - Overview
• Exhibit 161: Theravance Biopharma Inc. - Product / Service
• Exhibit 162: Theravance Biopharma Inc. - Key offerings

• 12.17 Viatris Inc.
• Exhibit 163: Viatris Inc. - Overview
• Exhibit 164: Viatris Inc. - Business segments
• Exhibit 165: Viatris Inc. - Key offerings
• Exhibit 166: Viatris Inc. - Segment focus

13 Appendix

• 13.1 Scope of the report

• 13.2 Inclusions and exclusions checklist 
• Exhibit 167: Inclusions checklist
• Exhibit 168: Exclusions checklist

• 13.3 Currency conversion rates for US$ 
• Exhibit 169: Currency conversion rates for US$

• 13.4 Research methodology
• Exhibit 170: Research methodology
• Exhibit 171: Validation techniques employed for market sizing
• Exhibit 172: Information sources

• 13.5 List of abbreviations 
• Exhibit 173: List of abbreviations

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact

Technavio Research

Jesse Maida

Media & Marketing Executive

US: +1 844 364 1100

UK: +44 203 893 3200

Email: media@technavio.com

Website: www.technavio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/chronic-obstructive-pulmonary-disease-drugs-market-driving-factors-industry-challenges-segmentation-key-vendor-analysis-leading-countries-and-market-size-and-forecast-2023-2027---technavio-301726661.html

SOURCE Technavio